News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Alnylam Pharmaceuticals
NEWS
JOBS
IN THE PRESS
NEWS
Policy
Sparring Over Trade Secrets, Dicerna Brings New Antitrust Suit Against Alnylam
August 11, 2017
·
1 min read
Drug Development
Could Alnylam Have An Edge On This Smaller Biotech In Rare Disease?
July 11, 2017
·
1 min read
Drug Development
Why All Eyes Will be on Alnylam and Any Updates of Its APOLLO Phase III Trial This Friday
May 11, 2017
·
2 min read
Genetown
Alnylam’s Patisiran, Chronicle Of A Death Foretold
April 11, 2017
·
1 min read
Business
Filings Reveal Alnylam CEO’s Pay Dropped Almost 80% in 2016
March 21, 2017
·
2 min read
Drug Development
Alnylam Execs Open Up About Patient Deaths in Abandoned Drug Trial
November 4, 2016
·
2 min read
Drug Development
The Ripple Effect of Alnylam’s Blow-up Yesterday
October 7, 2016
·
3 min read
Drug Development
Alnylam Stock Craters After Deaths Cause Clinical Trial to End
October 5, 2016
·
3 min read
4 Things To Learn From Medicine Development, Says Alnylam CEO
October 3, 2016
·
1 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Business
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
February 11, 2021
·
33 min read
Business
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial Results
January 28, 2021
·
2 min read
Genetown
Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021
·
2 min read
Genetown
Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day
December 15, 2020
·
16 min read
Genetown
Alnylam to Webcast Virtual R&D Day
December 8, 2020
·
2 min read
Business
CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”)
December 8, 2020
·
8 min read
Genetown
Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company’s Approved Therapies
December 7, 2020
·
11 min read
Drug Development
Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1
December 3, 2020
·
10 min read
Genetown
Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference
November 25, 2020
·
1 min read
FDA
Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients
November 24, 2020
·
19 min read
